Llorente/Sandvig publish potential biomarkers for prostate cancer
Llorente (left) and Sandvig
Alicia Llorente and Kirsten Sandvig, Department of Biochemistry, Institute for Cancer Research and Centre for Cancer Biomedicine, have recently published in Molecular and Cellular Proteomics (impact factor 8.4) a proteomic analysis of microvesicles released from a human prostate cancer cell line. Most of the 266 proteins identified have previously been reported to be present in vesicles released from other cell types, but several proteins seem to be specific for prostate cancer cells. Since microvesicles can reach biological fluids, these proteins are thus potentially useful as new non invasive biomarkers for detection, diagnosis and/or prognosis of prostate cancer.
From major journals, first or last author from the Institute for Cancer Research
Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L(2025) Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer Breast Cancer Res, 27(1), 131 DOI 10.1186/s13058-025-02082-x, PubMed 40660361
Chen Y, He L, Ianevski A, Nader K, Ruokoranta T, Linnavirta N, Miettinen JJ, Vähä-Koskela M, Vänttinen I, Kuusanmäki H, Kontro M, Porkka K, Wennerberg K, Heckman CA, Giri AK, Aittokallio T(2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia Cancer Res, 85(14), 2753-2768 DOI 10.1158/0008-5472.CAN-24-3840, PubMed 40354625
Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L(2025) Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer Breast Cancer Res, 27(1), 131 DOI 10.1186/s13058-025-02082-x, PubMed 40660361